325 related articles for article (PubMed ID: 19588140)
1. Ambulatory administration of 5-day infusion ifosfamide+mesna: a pilot study in sarcoma patients.
Coriat R; Mir O; Camps S; Ropert S; Billemont B; Leconte M; Larousserie F; Anract P; Alexandre J; Goldwasser F
Cancer Chemother Pharmacol; 2010 Feb; 65(3):491-5. PubMed ID: 19588140
[TBL] [Abstract][Full Text] [Related]
2. High-dose ifosfamide with hematopoietic growth factor support in advanced bone and soft tissue sarcomas.
Yalcin B; Pamir A; Buyukcelik A; Utkan G; Akbulut H; Demirkazik A; Icli F
Exp Oncol; 2004 Dec; 26(4):320-5. PubMed ID: 15627067
[TBL] [Abstract][Full Text] [Related]
3. Phase III trial of two investigational schedules of ifosfamide compared with standard-dose doxorubicin in advanced or metastatic soft tissue sarcoma: a European Organisation for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group Study.
Lorigan P; Verweij J; Papai Z; Rodenhuis S; Le Cesne A; Leahy MG; Radford JA; Van Glabbeke MM; Kirkpatrick A; Hogendoorn PC; Blay JY;
J Clin Oncol; 2007 Jul; 25(21):3144-50. PubMed ID: 17634494
[TBL] [Abstract][Full Text] [Related]
4. Doxorubicin, ifosfamide, and dacarbazine (AID) with mesna uroprotection for advanced untreated sarcoma: a phase I study.
Elias AD; Antman KH
Cancer Treat Rep; 1986 Jul; 70(7):827-33. PubMed ID: 3087617
[TBL] [Abstract][Full Text] [Related]
5. Ifosfamide combination regimens for soft-tissue sarcoma.
Stuart-Harris R; Dalley D; Bell DR; Levi J; Simes RJ; Wiltshaw E
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S185-8. PubMed ID: 8453695
[TBL] [Abstract][Full Text] [Related]
6. Ifosfamide and mesna: response and toxicity at standard- and high-dose schedules.
Antman KH; Elias A; Ryan L
Semin Oncol; 1990 Apr; 17(2 Suppl 4):68-73. PubMed ID: 2110386
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of adjuvant single-agent ifosfamide in uterine sarcoma.
Kushner DM; Webster KD; Belinson JL; Rybicki LA; Kennedy AW; Markman M
Gynecol Oncol; 2000 Aug; 78(2):221-7. PubMed ID: 10926807
[TBL] [Abstract][Full Text] [Related]
8. Ifosfamide in the treatment of soft-tissue sarcomas: experience at the West German Tumor Center, Essen.
Schütte J; Kellner R; Seeber S
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S194-8. PubMed ID: 8453697
[TBL] [Abstract][Full Text] [Related]
9. [Preliminary result of advanced soft tissue sarcoma treated by MAID regimen].
Huang YH; Wen XP; Hu L
Ai Zheng; 2002 Aug; 21(8):907-9. PubMed ID: 12478905
[TBL] [Abstract][Full Text] [Related]
10. High-dose ifosfamide as second- or third-line chemotherapy in refractory bone and soft tissue sarcoma patients.
Lee SH; Chang MH; Baek KK; Han B; Lim T; Lee J; Park JO
Oncology; 2011; 80(3-4):257-61. PubMed ID: 21734417
[TBL] [Abstract][Full Text] [Related]
11. A pilot study of cisplatin, ifosfamide and mesna in the treatment of malignant mixed mesodermal tumors of the ovary.
Crotzer DR; Wolf JK; Gano JB; Gershenson DM; Levenback C
Gynecol Oncol; 2007 May; 105(2):399-403. PubMed ID: 17292457
[TBL] [Abstract][Full Text] [Related]
12. Sequential dose-dense doxorubicin and ifosfamide for advanced soft tissue sarcomas: a Phase II trial by the Spanish Group for Research on Sarcomas (GEIS).
Maurel J; Fra J; López-Pousa A; García del Muro X; Balañá C; Casado A; Martín J; Martínez-Trufero J; de las Peñas R; Buesa JM;
Cancer; 2004 Apr; 100(7):1498-506. PubMed ID: 15042685
[TBL] [Abstract][Full Text] [Related]
13. Pilot study of ambulatory infusional delivery of a multidrug regimen: ifosfamide, carboplatin and etoposide (ICE).
Lokich J; Anderson N; Moore C; Bern M; Coco F; Dow E
J Infus Chemother; 1996; 6(1):39-42. PubMed ID: 8748006
[TBL] [Abstract][Full Text] [Related]
14. Phase 1 European Organisation for Research and Treatment of Cancer study determining safety of pegylated liposomal doxorubicin (Caelyx) in combination with ifosfamide in previously untreated adult patients with advanced or metastatic soft tissue sarcomas.
Nielsen OS; Reichardt P; Christensen TB; Pink D; Daugaard S; Hermans C; Marreaud S; van Glabbeke M; Blay J; Judson I
Eur J Cancer; 2006 Sep; 42(14):2303-9. PubMed ID: 16891112
[TBL] [Abstract][Full Text] [Related]
15. [Effect of modified MAID regimen for patients with advanced soft tissue sarcoma].
Li EX; Zhang YT; Shang JT; Xu Z; Geng Y; Li SM; Shi F; Wu YY
Ai Zheng; 2006 Aug; 25(8):1048-51. PubMed ID: 16965692
[TBL] [Abstract][Full Text] [Related]
16. Dana-Farber Cancer Institute studies in advanced sarcoma.
Antman KH; Elias A
Semin Oncol; 1990 Feb; 17(1 Suppl 2):7-15. PubMed ID: 2106162
[TBL] [Abstract][Full Text] [Related]
17. Ifosfamide plus doxorubicin in previously untreated patients with advanced soft-tissue sarcoma.
Schütte J; Mouridsen HT; Steward W; Santoro A; van Oosterom AT; Somers R; Blackledge G; Verweij J; Dombernowsky P; Thomas D
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S204-9. PubMed ID: 8453699
[TBL] [Abstract][Full Text] [Related]
18. Paclitaxel-ifosfamide-cisplatin as salvage chemotherapy in ovarian cancer patients pretreated with platinum compounds and paclitaxel.
Polyzos A; Kosmas C; Tsavaris N; Toufexi H; Lagadas A; Gogas H; Giannakopoulos K; Kouraklis G; Griniatsos J; Felekouras E; Tsigris C; Nikiteas N; Papadopoulos O; Giannopoulos A
Anticancer Res; 2007; 27(3B):1645-51. PubMed ID: 17595790
[TBL] [Abstract][Full Text] [Related]
19. Phase II trial of ifosfamide and cisplatin in the treatment of metastatic sarcomas: a Southwest Oncology Group study.
Budd GT; Metch B; Weiss SA; Weick JK; Fabian C; Stephens RL; Balcerzak SP
Cancer Chemother Pharmacol; 1993; 31 Suppl 2():S213-6. PubMed ID: 8453701
[TBL] [Abstract][Full Text] [Related]
20. Ifosfamide/liposomal daunorubicin is a well tolerated and active first-line chemotherapy regimen in advanced soft tissue sarcoma: results of a phase II study.
Siehl JM; Thiel E; Schmittel A; Hütter G; Deckert PM; Szelényi H; Keilholz U
Cancer; 2005 Aug; 104(3):611-7. PubMed ID: 15968689
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
